Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14136980 | 0.92 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL14030873 | 0.90 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL14048987 | 0.85 | OPRD1 (0.42) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6426855 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL12464666 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL2879579 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL12395525 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL2157463 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL3094737 | 0.77 | GRIN2B (0.50) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL2158340 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | SMN1; SMN2 1088/4885NPC1 146/4885RAB9A 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.